Vincent Serra

Vincent Serra has extensive experience in the biotechnology industry. Vincent is currently serving as the Chief Scientific and Operating Officer at NEOVACS SA since May 2020. Prior to that, they held roles such as Chief Scientific Officer and Chief Executive Officer at the same company.

In 2018, Vincent worked as a Senior Consultant at Biotech Consulting. Vincent also co-founded and served as the CEO of cerebrum therapeutics in 2018.

From 2016 to 2017, they held the position of Head of External Innovation at Pierre Fabre Group. During this time, they were also the Executive Partner of Pierre Fabre Fund for Innovation, responsible for managing potential sourcing projects and acting as a liaison between the executive partners and the top management of Pierre Fabre Laboratories.

Vincent's career includes co-founding ABIVAX in 2014, where they served as the Vice President of Research and Development for Viral Vaccine. Vincent played a key role in the stock-market listing and IPO of ABIVAX, raising significant funds for the company.

Vincent co-founded Wittycell in 2005 and served as the CEO and Chief Scientific Officer until 2014. Vincent'sresponsibilities included analyzing scientific projects, launching new ventures, and signing license agreements with various institutes.

Before that, Vincent was the CEO and Chief Scientific Officer of Anosys, a biotechnology company specialized in innovative products. Vincent also worked at AP Cells Inc as an Immunology Research Team Leader and completed their PhD at CEA.

Vincent Serra earned their PhD in Biology from Université Grenoble Alpes between 1994 and 1998.